<?xml version="1.0" encoding="UTF-8"?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
   <?properties open_access?>
   <front>
      <journal-meta>
         <journal-id journal-id-type="nlm-ta">AAPS J</journal-id>
         <journal-id journal-id-type="iso-abbrev">AAPS J</journal-id>
         <journal-title-group>
            <journal-title>The AAPS Journal</journal-title>
         </journal-title-group>
         <issn pub-type="epub">1550-7416</issn>
         <publisher>
            <publisher-name>Springer US</publisher-name>
            <publisher-loc>Boston</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
<!--

fact ('10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone->kcnq1 i=18568022', <chemotext_util.Fact object at 0x10c8b2f50>)
fact ('10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone->kcnq2 i=15634793', <chemotext_util.Fact object at 0x10c8b27d0>)
fact ('10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone->kcnq2 i=20208034', <chemotext_util.Fact object at 0x10c8b2890>)
fact ('10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone->kcnq3 i=20208034', <chemotext_util.Fact object at 0x10c8b2610>)
fact ('10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone->developmental disabilities i=20805988', <chemotext_util.Fact object at 0x10c8b2790>)
fact ('10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone->diabetes mellitus, type 2 i=18711366', <chemotext_util.Fact object at 0x10c8b2810>)
fact ('10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone->diabetes mellitus, type 2 i=18711367', <chemotext_util.Fact object at 0x10c8b25d0>)
fact ('10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone->diabetes mellitus, type 2 i=26551672', <chemotext_util.Fact object at 0x10c8b2650>)

-->
         <article-id pub-id-type="pmid">20805988</article-id>
         <article-id pub-id-type="pmc">2976985</article-id>
         <article-id pub-id-type="publisher-id">9226</article-id>
         <article-id pub-id-type="doi">10.1208/s12248-010-9226-9</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>White Paper</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>NonClinical Dose Formulation Analysis Method Validation and Sample Analysis</article-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" corresp="yes">
               <name>
                  <surname>Whitmire</surname>
                  <given-names>Monica Lee</given-names>
               </name>
               <address>
                  <email>monica.whitmire@mpiresearch.com</email>
               </address>
               <xref ref-type="aff" rid="Aff1" />
            </contrib>
            <contrib contrib-type="author">
               <name>
                  <surname>Bryan</surname>
                  <given-names>Peter</given-names>
               </name>
               <address>
                  <email>pbryan@celgene.com</email>
               </address>
               <xref ref-type="aff" rid="Aff2" />
            </contrib>
            <contrib contrib-type="author">
               <name>
                  <surname>Henry</surname>
                  <given-names>Teresa R.</given-names>
               </name>
               <address>
                  <email>trlamm@hotmail.com</email>
               </address>
               <xref ref-type="aff" rid="Aff3" />
            </contrib>
            <contrib contrib-type="author">
               <name>
                  <surname>Holbrook</surname>
                  <given-names>John</given-names>
               </name>
               <address>
                  <email>jah1957@ptd.net</email>
               </address>
            </contrib>
            <contrib contrib-type="author">
               <name>
                  <surname>Lehmann</surname>
                  <given-names>Paul</given-names>
               </name>
               <address>
                  <email>Paul.Lehmann@sanofi-aventis.com</email>
               </address>
               <xref ref-type="aff" rid="Aff4" />
            </contrib>
            <contrib contrib-type="author">
               <name>
                  <surname>Mollitor</surname>
                  <given-names>Thomas</given-names>
               </name>
               <address>
                  <email>thomas.mollitor@spcorp.com</email>
               </address>
            </contrib>
            <contrib contrib-type="author">
               <name>
                  <surname>Ohorodnik</surname>
                  <given-names>Susan</given-names>
               </name>
               <address>
                  <email>sohorodnik@gtxinc.com</email>
               </address>
               <xref ref-type="aff" rid="Aff5" />
            </contrib>
            <contrib contrib-type="author">
               <name>
                  <surname>Reed</surname>
                  <given-names>David</given-names>
               </name>
               <address>
                  <email>david_reed@merck.com</email>
               </address>
               <xref ref-type="aff" rid="Aff6" />
            </contrib>
            <contrib contrib-type="author">
               <name>
                  <surname>Wietgrefe</surname>
                  <given-names>Holly D.</given-names>
               </name>
               <address>
                  <email>wietgreh@advion.com</email>
               </address>
               <xref ref-type="aff" rid="Aff7" />
            </contrib>
            <aff id="Aff1">
               <label />
               MPI Research, 54943 North Main Street, Mattawan, Michigan USA
            </aff>
            <aff id="Aff2">
               <label />
               Celgene, Summit, New Jersey USA
            </aff>
            <aff id="Aff3">
               <label />
               Pharmavite, Mission Hills, California USA
            </aff>
            <aff id="Aff4">
               <label />
               Sanofi Aventis, Bridgewater, New Jersey USA
            </aff>
            <aff id="Aff5">
               <label />
               GTx, Inc., Memphis, Tennessee USA
            </aff>
            <aff id="Aff6">
               <label />
               Merck, West Point, PA USA
            </aff>
            <aff id="Aff7">
               <label />
               Advion, Ithaca, New York USA
            </aff>
         </contrib-group>
         <pub-date pub-type="epub">
            <day>14</day>
            <month>8</month>
            <year>2010</year>
         </pub-date>
         <pub-date pub-type="collection">
            <month>12</month>
            <year>2010</year>
         </pub-date>
         <volume>12</volume>
         <issue>4</issue>
         <fpage>628</fpage>
         <lpage>634</lpage>
         <history>
            <date date-type="received">
               <day>30</day>
               <month>4</month>
               <year>2010</year>
            </date>
            <date date-type="accepted">
               <day>6</day>
               <month>7</month>
               <year>2010</year>
            </date>
         </history>
         <permissions>
            <copyright-statement>© The Author(s) 2010</copyright-statement>
         </permissions>
         <abstract id="Abs1">
            <p>Nonclinical dose formulation analysis methods are used to confirm test article concentration and homogeneity in formulations and determine formulation stability in support of regulated nonclinical studies. There is currently no regulatory guidance for nonclinical dose formulation analysis method validation or sample analysis. Regulatory guidance for the validation of analytical procedures has been developed for drug product/formulation testing; however, verification of the formulation concentrations falls under the framework of GLP regulations (not GMP). The only current related regulatory guidance is the bioanalytical guidance for method validation. The fundamental parameters for bioanalysis and formulation analysis validations that overlap include: recovery, accuracy, precision, specificity, selectivity, carryover, sensitivity, and stability. Divergence in bioanalytical and drug product validations typically center around the acceptance criteria used. As the dose formulation samples are not true “unknowns”, the concept of quality control samples that cover the entire range of the standard curve serving as the indication for the confidence in the data generated from the “unknown” study samples may not always be necessary. Also, the standard bioanalytical acceptance criteria may not be directly applicable, especially when the determined concentration does not match the target concentration. This paper attempts to reconcile the different practices being performed in the community and to provide recommendations of best practices and proposed acceptance criteria for nonclinical dose formulation method validation and sample analysis.</p>
         </abstract>
         <kwd-group xml:lang="en">
            <title>KEY WORDS</title>
            <kwd>acceptance criteria</kwd>
            <kwd>formulation method validation</kwd>
            <kwd>formulation sample analysis</kwd>
            <kwd>nonclinical dose formulation analysis</kwd>
            <kwd>test article concentration and homogeneity</kwd>
         </kwd-group>
         <custom-meta-group>
            <custom-meta>
               <meta-name>issue-copyright-statement</meta-name>
               <meta-value>© American Association of Pharmaceutical Scientists 2010</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <body>
     <sec id="Sec1" sec-type="introduction">
       <title>INTRODUCTION</title>
       <p>
         This is test data.

         The 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone influences developmental disabilities which has something to do with osteoarthritis and Diabetes Mellitus, Type 2.

       </p>
     </sec>
   </body>
   <back>
      <fn-group>
         <fn>
            <p>
               <bold>Definitions</bold>
            </p>
            <p>Accuracy Calculations:</p>
            <p>
               <inline-formula id="IEq7">
                  <alternatives>
                     <tex-math id="M7">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ \% {\hbox{ Recovery}} = \left( {\hbox{found concentration}} \right)/\left( {\hbox{nominal concentration}} \right) \times 100 $$\end{document}</tex-math>
                     <inline-graphic xlink:href="12248_2010_9226_Article_IEq7.gif" />
                  </alternatives>
               </inline-formula>
            </p>
            <p>
               <inline-formula id="IEq8">
                  <alternatives>
                     <tex-math id="M8">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ \% {\hbox{ Relative Error }}\left( {\% {\hbox{Deviation}}} \right) = \left[ {\left( {\hbox{found concentration}} \right) - \left( {\hbox{nominal concentration}} \right)} \right]/\left( {\hbox{nominal concentration}} \right) \times 100 $$\end{document}</tex-math>
                     <inline-graphic xlink:href="12248_2010_9226_Article_IEq8.gif" />
                  </alternatives>
               </inline-formula>
            </p>
            <p>Feed: Feeds or chows are blended from various raw materials and additives and are formulated according to the specific requirements of the target animal. They may be meals, pellets or crumbles.</p>
            <p>Intra-run: within one day or analytical run or analytical sequence</p>
            <p>Inter-run: between days or analytical runs or analytical sequences</p>
            <p>Nominal concentration: The theoretical concentration, corrected for salt form and purity (as applicable), of a formulation based on the amount of analyte weighed per total volume of analyte plus vehicle.</p>
            <p>Precision Calculations:</p>
            <p>
               <inline-formula id="IEq9">
                  <alternatives>
                     <tex-math id="M9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ \% {\hbox{ Relative Standard Deviation }}\left( {\% {\hbox{ Coefficient of Variation}}} \right) = {\hbox{SD}} \times 100/{\hbox{Mean}} $$\end{document}</tex-math>
                     <inline-graphic xlink:href="12248_2010_9226_Article_IEq9.gif" />
                  </alternatives>
               </inline-formula>
            </p>
            <p>Note:% Relative Standard Deviation is appropriate only for data sets containing 3 or more points.</p>
            <p>Quality Control Sample: A solution, suspension or solid containing test article in formulation vehicle designed to mimic actual dosage formulations.</p>
            <p>Solution: A solution is a homogeneous mixture composed of two or more substances dissolved in a solvent.</p>
            <p>Solid: A solid object does not flow to take on the shape of its container, nor does it expand to fill the entire volume available. Examples are powders, powders in capsules and tablets.</p>
            <p>Suspension: A suspension is a heterogeneous mixture in which solute-like particles may settle out of solvent-like phase some time after their introduction.</p>
            <p>True Solution: A “true solution” is a solution in which the analyte is completely dissolved in the liquid phase. If a true solution is filtered, then the filtrate and the retentate generate the same concentration value. If a true solution is centrifuged, then no particles are observed. If a true solution is analyzed utilizing a solubility scanner, then the particle size maintains a horizontal axis across the solubility range.</p>
         </fn>
      </fn-group>
      <ack>
         <title>Acknowledgements</title>
         <p>The authors would like to thank the following: John Buckholz, B.S., Brian Burback Ph.D., Binh Do, Dannette Doolittle, Ph.D., Rodrigo Laureano, M.S., Josef Ludwig, B.S., MBA, Emily Mainstone, B.S., Stacy Marden, Ph.D., Tony Nakhla, M.S., Shaundel Percey, B.S., MT (ASCP), Yuan-Shek Chen, Ph.D., Phillip J. Wang, Ph.D, MBA, and Laixin Wang, Ph.D.</p>
         <sec id="d30e692">
            <title>Open Access</title>
            <p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
         </sec>
      </ack>
      <ref-list id="Bib1">
         <title>References</title>
         <ref id="CR1">
            <label>1.</label>
            <mixed-citation publication-type="other">
               FDA Nonclinical Laboratory Studies Good Laboratory Practice Regulations. Available at:
               <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ora/compliance_ref/bimo/glp/78fr-glpfinalrule.pdf">http://www.fda.gov/ora/compliance_ref/bimo/glp/78fr-glpfinalrule.pdf</ext-link>
            </mixed-citation>
         </ref>
         <ref id="CR2">
            <label>2.</label>
            <mixed-citation publication-type="other">
               FDA 21 CFR Part 58 Good Laboratory Practice Regulations Final Rule. Available at:
               <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ora/compliance_ref/bimo/glp/87fr-glpamendment.pdf">http://www.fda.gov/ora/compliance_ref/bimo/glp/87fr-glpamendment.pdf</ext-link>
            </mixed-citation>
         </ref>
         <ref id="CR3">
            <label>3.</label>
            <mixed-citation publication-type="other">Organisation for Economic Co-operation and Development (OECD) Principles of Good Laboratory Practice, [ENV/MC/CHEM(98)17], 26 Jan 1998.</mixed-citation>
         </ref>
         <ref id="CR4">
            <label>4.</label>
            <mixed-citation publication-type="other">Japanese Ministry of Health, Labor and Welfare (MHLW) No. 21, March 26, 1997</mixed-citation>
         </ref>
         <ref id="CR5">
            <label>5.</label>
            <mixed-citation publication-type="other">FDA. Guidance for Industry: Bioanalytical Method Validation. In: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, May 2001.</mixed-citation>
         </ref>
         <ref id="CR6">
            <label>6.</label>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Shah</surname>
                     <given-names>V</given-names>
                  </name>
                  <name>
                     <surname>Midha</surname>
                     <given-names>K</given-names>
                  </name>
                  <name>
                     <surname>Dighe</surname>
                     <given-names>S</given-names>
                  </name>
                  <name>
                     <surname>McGilveray</surname>
                     <given-names>I</given-names>
                  </name>
                  <name>
                     <surname>Skelly</surname>
                     <given-names>J</given-names>
                  </name>
                  <name>
                     <surname>Yacobi</surname>
                     <given-names>A</given-names>
                  </name>
                  <etal />
               </person-group>
               <article-title>Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report</article-title>
               <source>Eur J Drug Metab Pharmacokinet</source>
               <year>1991</year>
               <volume>16</volume>
               <issue>4</issue>
               <fpage>249</fpage>
               <lpage>255</lpage>
               <pub-id pub-id-type="doi">10.1007/BF03189968</pub-id>
               <pub-id pub-id-type="pmid">1823867</pub-id>
            </element-citation>
         </ref>
         <ref id="CR7">
            <label>7.</label>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Shah</surname>
                     <given-names>V</given-names>
                  </name>
                  <name>
                     <surname>Midha</surname>
                     <given-names>K</given-names>
                  </name>
                  <name>
                     <surname>Findlay</surname>
                     <given-names>J</given-names>
                  </name>
                  <name>
                     <surname>Hill</surname>
                     <given-names>H</given-names>
                  </name>
                  <name>
                     <surname>Hulse</surname>
                     <given-names>J</given-names>
                  </name>
                  <name>
                     <surname>McGilveray</surname>
                     <given-names>I</given-names>
                  </name>
                  <etal />
               </person-group>
               <article-title>Bioanalytical method validation—a revisit with a decade of progress</article-title>
               <source>Pharm Res</source>
               <year>2000</year>
               <volume>17</volume>
               <issue>12</issue>
               <fpage>1551</fpage>
               <lpage>7</lpage>
               <pub-id pub-id-type="doi">10.1023/A:1007669411738</pub-id>
               <pub-id pub-id-type="pmid">11303967</pub-id>
            </element-citation>
         </ref>
         <ref id="CR8">
            <label>8.</label>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Viswanathan</surname>
                     <given-names>C</given-names>
                  </name>
                  <name>
                     <surname>Bansal</surname>
                     <given-names>S</given-names>
                  </name>
                  <name>
                     <surname>Booth</surname>
                     <given-names>B</given-names>
                  </name>
                  <name>
                     <surname>DeStefano</surname>
                     <given-names>A</given-names>
                  </name>
                  <name>
                     <surname>Rose</surname>
                     <given-names>M</given-names>
                  </name>
                  <name>
                     <surname>Sailstad</surname>
                     <given-names>J</given-names>
                  </name>
                  <etal />
               </person-group>
               <article-title>Workshop/conference report—quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays</article-title>
               <source>Pharm Res</source>
               <year>2007</year>
               <volume>24</volume>
               <issue>10</issue>
               <fpage>1962</fpage>
               <lpage>73</lpage>
               <pub-id pub-id-type="doi">10.1007/s11095-007-9291-7</pub-id>
               <pub-id pub-id-type="pmid">17458684</pub-id>
            </element-citation>
         </ref>
         <ref id="CR9">
            <label>9.</label>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Shah</surname>
                     <given-names>V</given-names>
                  </name>
               </person-group>
               <article-title>The history of bioanalytical method validation and regulation: evolution of a guidance document on bioanalytical methods validation</article-title>
               <source>The AAPS Journal</source>
               <year>2007</year>
               <volume>9</volume>
               <issue>1</issue>
               <fpage>E43</fpage>
               <lpage>7</lpage>
               <pub-id pub-id-type="doi">10.1208/aapsj0901005</pub-id>
            </element-citation>
         </ref>
         <ref id="CR10">
            <label>10.</label>
            <mixed-citation publication-type="other">USP 32-NF 27 (United States Pharmacopeial Convention, Rockville, MD, 2009), pp. 3988–91.</mixed-citation>
         </ref>
         <ref id="CR11">
            <label>11.</label>
            <mixed-citation publication-type="other">FDA, “Analytical Procedures and Methods Validation: Chemistry, Manufacturing and Controls.” Federal Register (Notices) 65(160), 52,776-52,777 (August 2000).</mixed-citation>
         </ref>
         <ref id="CR12">
            <label>12.</label>
            <mixed-citation publication-type="other">Q2A “Text on validation of analytical procedures.” International Conference on Harmonization. Fed Regist. 1995; 60: 11260</mixed-citation>
         </ref>
         <ref id="CR13">
            <label>13.</label>
            <mixed-citation publication-type="other">Q2B “validation of analytical procedures: methodology.” International Conference on Harmonization. Federal Register. 1996; 60: 11260.</mixed-citation>
         </ref>
         <ref id="CR14">
            <label>14.</label>
            <mixed-citation publication-type="other">Q2 (R1) “Validation of analytical procedures: text and methodology.” International Conference on Harmonization. Federal Register. 1997; 62: 27463–27467.</mixed-citation>
         </ref>
         <ref id="CR15">
            <label>15.</label>
            <mixed-citation publication-type="other">“International Conference on Harmonization; Draft Guidance on Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Products: Chemical Substances.” Federal Register (Notices) 2000; 65(251): 83041–63.</mixed-citation>
         </ref>
         <ref id="CR16">
            <label>16.</label>
            <mixed-citation publication-type="other">“Harmonized guidelines for single-laboratory validation of methods of analysis.” International Union of Pure and Applied Chemistry (IUPAC) Technical Report. Pure Appl Chem. 2002; 74(5): 835–55.</mixed-citation>
         </ref>
         <ref id="CR17">
            <label>17.</label>
            <mixed-citation publication-type="other">
               FDA CDER Guidance for Industry Analytical Procedures and Methods Validation. Available at:
               <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/cder/guidance/2396dft.pdf">http://www.fda.gov/cder/guidance/2396dft.pdf</ext-link>
            </mixed-citation>
         </ref>
         <ref id="CR18">
            <label>18.</label>
            <mixed-citation publication-type="other">
               FDA Guidance for Industry Good Laboratory Practices Questions and Answers revised July 2007. Available at:
               <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ora/compliance_ref/bimo/glp/81GLP-qanda.pdf">http://www.fda.gov/ora/compliance_ref/bimo/glp/81GLP-qanda.pdf</ext-link>
            </mixed-citation>
         </ref>
         <ref id="CR19">
            <label>19.</label>
            <mixed-citation publication-type="other">
               FDA CDER Reviewer Guidance Validation of Chromatographic Methods. Available at:
               <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/cder/guidance/cmc3_rev.pdf">http://www.fda.gov/cder/guidance/cmc3_rev.pdf</ext-link>
            </mixed-citation>
         </ref>
         <ref id="CR20">
            <label>20.</label>
            <mixed-citation publication-type="other">FDA. Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production. In: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, October 2006.</mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
